Here’s what you should know.
1. The companies entered into the agreement after evidence emerged suggesting the anti-PD-1 therapy’s immune activity enhances when combined with a MEK inhibitor.
2. The clinical trial aims to establish a recommended dose regimen, and to explore preliminary several novel regimens’ anti-tumor activity.
3. The companies expect the trial to begin in the second half of 2017. The first study’s results will shape future clinical developmental decisions.
4. Merck is sponsoring the trial.
More articles on gastroenterology:
European scientists developing advanced endoscope — 3 insights
GI leader to know: Dr. Jennifer Dorfmeister of Illinois Gastro
Unique enzyme could allow gluten-sensitive patients to digest gluten — 3 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
